# The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

> **NCT00216515** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 102 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00216515
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216515, "The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00216515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*